Table 1 Baseline demographics and clinical characteristics of the pooled cohorts from 8 trials of linagliptin versus total comparators (placebo and active treatment)
Linagliptin (n= 3319) | Total comparators (n= 1920) | |
|---|---|---|
Gender, % of patients | ||
Male/female | 53.7/46.3 | 58.6/41.4 |
Age, years | 58 ± 10 | 58 ± 10 |
BMI, kg/m2 | 28.8 ± 5.0 | 29.1 ± 4.9 |
Race, % of patients | ||
White | 59.7 | 61.8 |
Black | 1.4 | 1.6 |
Asian | 38.9 | 36.6 |
HbA1c, mmol/mol | 65 ± 10 | 64 ± 10 |
HbA1c, % | 8.1 ± 0.9 | 8.0 ± 0.9 |
FPG, mmol/L | 9.3 ± 2.4 | 9.4 ± 2.3 |
Diabetes duration (known), % of patients | ||
≤ 1 years | 12.1 | 12.2 |
1-5 years | 34.8 | 36.6 |
> 5 years | 53.1 | 51.2 |
Previous oral glucose-lowering agents, % of patients | ||
None | 17.3 | 17.3 |
1 | 42.8 | 49.9 |
2 | 39.7 | 32.5 |
≥ 3 | 0.2 | 0.2 |
CV risk factors, % of patients | ||
Metabolic syndrome* | 60.3 | 61.7 |
Coronary artery disease | 10.4 | 11.0 |
Cerebrovascular disease | 2.9 | 3.9 |
Peripheral artery disease | 2.3 | 3.0 |
Hypertension | 63.8 | 66.0 |
Ex-/current smoker | 22.9/14.4 | 24.2/15.9 |
eGFR using CG/MDRD formulae, % of patients | ||
Normal | 74.9/55.4 | 77.3/55.4 |
Mildly impaired | 19.9/37.3 | 18.5/38.1 |
Moderately impaired | 2.2/4.3 | 1.9/4.3 |
Severely impaired | 0.1/0.1 | 0.1/0.1 |
CV medication, % of patients | ||
Acetyl-salicylic acid | 29.5 | 30.5 |
Antihypertensive | 60.0 | 63.0 |
Lipid-lowering therapy | 39.5 | 42.1 |
Any of the above | 72.8 | 75.5 |
Framingham 10-year CV risk score | ||
Score, % | 9.8 ± 8.2 | 10.3 ± 8.4 |
Score > 15%, % of patients | 27.8 | 31.1 |